Instruction for use: VenlafaxineI want this, give me price
Dosage form: tablets; capsules
Active substance: Venlafaxine*
The nosological classification (ICD-10)
F32 Depressive episode: Adynamic subdepression; Astheno-adynamic subdepressive states; Asthenoadressive disorder; Astheno-depressive disorder; Asthenodepressive state; Astheno-depressive state; Major Depressive Disorder; Vyaloapatichesky depression with retardation; Double Depression; Depressive pseudodement; Depressive illness; Depressive mood disorder; Depressive disorder; Depressive mood disorder; Depressive state; Depressive disorders; Depressive syndrome; Depressive syndrome larviated; Depressive syndrome in psychoses; Depressed masks; Depression; Depression Depletion; Depression with the phenomena of inhibition within the framework of cyclothymia; Depression is smiling; Involutional depression; Involutionary melancholy; Involutional depression; Manic-depressive disorder; Masked Depression; Melancholic Attack; Neurotic depression; Neurotic depression; Shallow Depression; Organic depression; Organic depressive syndrome; Simple depression; Simple melancholic syndrome; Psychogenic depression; Reactive depression; Reactive depression with moderate psychopathological symptoms; Reactive depressive states; Reactive depression; Recurrent depression; Seasonal depressive syndrome; Severostatic depression; Senile Depression; Symptomatic Depression; Somatogenic depression; Cyclotymic depression; Exogenous depression; Endogenous depression; Endogenous Depressive Conditions; Endogenous Depression; Endogenous depressive syndrome
F33 Recurrent depressive disorder: Major depressive disorder; Secondary depression; Double Depression; Depressive pseudodement; Depressive mood disorder; Depressive disorder; Depressive mood disorder; Depressive state; Depressive syndrome; Depressed masks; Depression; Depression is smiling; Involutional depression; Involutional depression; Masked Depression; Melancholic Attack; Reactive depression; Reactive depression with moderate psychopathological symptoms; Reactive depressive states; Exogenous depression; Endogenous depression; Endogenous Depressive Conditions; Endogenous Depression; Endogenous depressive syndrome
Tablets - 1 table.
venlafaxine hydrochloride 42.42 mg; 84.84 mg
(equivalent to 37.5 and 75 mg of venlafaxine, respectively)
auxiliary substances: MCC - 67.31 / 134.62 mg; pregelatinized starch 49.5 / 99 mg; silicon dioxide colloid (aerosil) - 0.82 / 1.64 mg; talc - 3.3 / 6.6 mg; magnesium stearate - 1.65 / 3.3 mg
Mode of action - antidepressant.
Dosing and Administration
Inside, with food, preferably at the same time, without chewing and washing down with liquid.
The recommended initial dose is 75 mg / day in two divided doses (37.5 mg twice a day). Depending on the tolerability and effectiveness, the dose can be gradually increased to 150 mg / day. If necessary, increase the dose to 225 mg / day. An increase in the dose of 75 mg / day can be done at intervals of 2 weeks or more, in case of clinical necessity, in view of the severity of the symptoms, it is possible to increase the dose in shorter periods, but not less than 4 days. Higher doses (up to a maximum daily dose of 375 mg / day in 2-3 sessions) require inpatient monitoring of patients. After achieving the necessary therapeutic effect, the daily dose can be gradually reduced to a minimum effective level.
Supportive therapy and prevention of relapse: supportive treatment can last 6 months or more. The minimum effective doses used in the treatment of a depressive episode are prescribed.
Special patient groups
Impaired renal function. With mild renal failure (GFR more than 30 ml / min), correction of the dosing regimen is not required. With moderate renal failure (GFR - 10-30 ml / min), the dose should be reduced by 25-50%. In connection with the elongation of venlafaxine T1 / 2 and its active metabolite (EFA), such patients should take the entire dose 1 time per day. It is not recommended to use venlafaxine in severe renal failure (GFR less than 10 ml / min), since there is no reliable data on such therapy. In hemodialysis, the daily dose should be reduced by 50%, the drug should be taken after the end of the hemodialysis session.
Violation of the function of the liver. With mild hepatic insufficiency (MF less than 14 s), correction of the dosing regimen is not required. With moderate hepatic insufficiency (IV 14 to 18 s), the daily dose should be reduced by 50% or more. It is not recommended to use venlafaxine in severe hepatic insufficiency, since there is no reliable data on such therapy.
Elderly patients. The elderly patient's age in the absence of any acute and chronic diseases does not require a dose change, however (as with the appointment of other medications) in the treatment of elderly patients requires caution. Elderly patients should be given the lowest effective dose. When the dose is raised, the patient must be under careful medical supervision.
Abolition of the drug
The discontinuation of taking the drug should be carried out gradually, in order to minimize the risk associated with the withdrawal of the drug. At the course of treatment for 6 weeks or more, the period of gradual withdrawal of the drug depends on the dose, duration of therapy and individual characteristics of the patient and should be at least 2 weeks.
Tablets, 37.5 mg or 75 mg. In contour acrylic packing from a film of PVC and a foil of aluminum printed varnished, 10 pieces. 1, 2, 3, 4 or 5 contour mesh packages in a pack of cardboard.
Conditions of leave from pharmacies
Storage conditions for Venlafaxine
In the dark place at a temperature of no higher than 25 ° C.
Keep out of the reach of children.
Shelf life of Venlafaxine
Do not use after the expiry date printed on the package.